Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-08-01
|
| Series: | Biologics: Targets & Therapy |
| Online Access: | http://www.dovepress.com/current-status-of-vandetanib-zd6474-in-the-treatment-of-non-small-cell-a5138 |
| _version_ | 1818905755394244608 |
|---|---|
| author | Jaclyn Flanigan Hari Deshpande Scott Gettinger |
| author_facet | Jaclyn Flanigan Hari Deshpande Scott Gettinger |
| author_sort | Jaclyn Flanigan |
| collection | DOAJ |
| description | Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis of multiple malignancies, including non-small cell lung cancer (NSCLC). Indeed, inhibitors of each pathway have been approved by the US Food and Drug Administration for use in advanced NSCLC. As there is considerable cross talk between these pathways, dual inhibition with such agents has become an attractive strategy, with encouraging Phase II clinical trial data to date. The convenience of one oral agent targeting both pathways is clear, and clinical trials have established the maximum tolerated daily dose of vandetanib, with data from randomized Phase III trials emerging. This report will review completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the future of this agent in NSCLC.Keywords: Zactima, ZD6474, non-small cell lung cancer, vandetanib |
| first_indexed | 2024-12-19T21:28:22Z |
| format | Article |
| id | doaj.art-cf568a52e46640e89d9b6362ec98daa2 |
| institution | Directory Open Access Journal |
| issn | 1177-5475 1177-5491 |
| language | English |
| last_indexed | 2024-12-19T21:28:22Z |
| publishDate | 2010-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Biologics: Targets & Therapy |
| spelling | doaj.art-cf568a52e46640e89d9b6362ec98daa22022-12-21T20:05:02ZengDove Medical PressBiologics: Targets & Therapy1177-54751177-54912010-08-012010default237243Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancerJaclyn FlaniganHari DeshpandeScott GettingerJaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis of multiple malignancies, including non-small cell lung cancer (NSCLC). Indeed, inhibitors of each pathway have been approved by the US Food and Drug Administration for use in advanced NSCLC. As there is considerable cross talk between these pathways, dual inhibition with such agents has become an attractive strategy, with encouraging Phase II clinical trial data to date. The convenience of one oral agent targeting both pathways is clear, and clinical trials have established the maximum tolerated daily dose of vandetanib, with data from randomized Phase III trials emerging. This report will review completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the future of this agent in NSCLC.Keywords: Zactima, ZD6474, non-small cell lung cancer, vandetanibhttp://www.dovepress.com/current-status-of-vandetanib-zd6474-in-the-treatment-of-non-small-cell-a5138 |
| spellingShingle | Jaclyn Flanigan Hari Deshpande Scott Gettinger Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer Biologics: Targets & Therapy |
| title | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| title_full | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| title_fullStr | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| title_full_unstemmed | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| title_short | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| title_sort | current status of vandetanib zd6474 in the treatment of non small cell lung cancer |
| url | http://www.dovepress.com/current-status-of-vandetanib-zd6474-in-the-treatment-of-non-small-cell-a5138 |
| work_keys_str_mv | AT jaclynflanigan currentstatusofvandetanibzd6474inthetreatmentofnonsmallcelllungcancer AT harideshpande currentstatusofvandetanibzd6474inthetreatmentofnonsmallcelllungcancer AT scottgettinger currentstatusofvandetanibzd6474inthetreatmentofnonsmallcelllungcancer |